Pharma company Invivyd, Inc. just announced it is working with the US Food and Drug Administration (FDA) on a pathway to rapid approval for a product it calls an “alternative” to COVID-19 vaccines. The novel monoclonal antibody-based treatment, catchily named VYD2311 for now, offers a different way of preventing COVID infections compared with the existing vaccines. The rest of this article is behind a paywall. Please sign in or subscribe to access the full content.

What are monoclonal antibodies?

Monoclonal antibodies (mAbs) are proteins designed and made in a lab that mimic natural human antibodies produced by the immune system. Since science figured out that it was possible to make these in the mid-70s, we’ve really gone to town with them.

“The number of approved and marketed antibody

See Full Page